Spironolactone and Rosuvastatin Interaction

Why This Combination Comes Up

Spironolactone at 50 to 200 mg daily is prescribed off-label for hormonal acne in women of reproductive age, and rosuvastatin (Crestor) is among the most commonly dispensed statins in the United States, with over 28 million prescriptions filled in 2023 according to ClinCalc drug usage statistics. The overlap population includes women over 35 managing both adult-onset acne and dyslipidemia, as well as heart-failure patients on mineralocorticoid receptor antagonists who require lipid-lowering therapy.

The RALES trial (N=1,663) established spironolactone's mortality benefit in severe heart failure [1]. Separately, the JUPITER trial (N=17,802) demonstrated rosuvastatin 20 mg reduced major cardiovascular events by 44% in patients with elevated hs-CRP [2]. Clinicians managing patients on both drugs need clarity on whether pharmacokinetic or pharmacodynamic interactions alter the risk-benefit calculus.

Pharmacokinetic Analysis: No Major CYP Conflict

Spironolactone undergoes extensive first-pass metabolism via CYP3A4 and, to a lesser extent, CYP2C8, producing active metabolites canrenone and 7-alpha-thiomethylspirolactone [3]. Rosuvastatin is distinct among statins because approximately 90% of the circulating drug remains unchanged. Its clearance depends primarily on hepatic uptake transporters (OATP1B1, OATP1B3) and efflux via BCRP, not cytochrome P450 enzymes [4].

This means the two drugs do not compete for the same metabolic enzymes. Unlike atorvastatin or simvastatin (both CYP3A4 substrates), rosuvastatin avoids the enzyme pathway that processes spironolactone. The FDA label for rosuvastatin confirms that CYP3A4 inhibitors do not meaningfully alter its plasma concentration [4].

Transporter-Level Interaction: OATP1B1/1B3 Considerations

Rosuvastatin depends on organic anion transporting polypeptides (OATP1B1 and OATP1B3) for hepatic uptake. Drugs that inhibit these transporters can raise rosuvastatin plasma levels and increase myopathy risk. The FDA label lists cyclosporine, certain protease inhibitors, and gemfibrozil as clinically significant OATP inhibitors [4].

Spironolactone demonstrates weak OATP1B1 inhibition in vitro (IC₅₀ values exceeding 100 µM in transfected cell assays), but therapeutic plasma concentrations of spironolactone and canrenone peak around 0.5 to 1.5 µM [5]. The ratio of unbound plasma concentration to IC₅₀ falls well below the 0.1 threshold that FDA draft guidance uses to predict clinical relevance [6]. No published pharmacokinetic study has demonstrated a measurable increase in rosuvastatin AUC when co-administered with spironolactone at standard doses.

The clinical translation: spironolactone is unlikely to raise rosuvastatin exposure enough to trigger dose-dependent adverse effects like myalgia or rhabdomyolysis. This contrasts sharply with cyclosporine, which increases rosuvastatin AUC 7-fold and necessitates a 5 mg dose cap [4].

Pharmacodynamic Concern: Potassium Elevation

The more relevant interaction is pharmacodynamic. Spironolactone blocks the mineralocorticoid receptor in the distal nephron, reducing potassium excretion. Mean serum potassium rises 0.3 to 0.5 mEq/L at the 100 mg daily dose used for acne [7]. In heart-failure populations on higher doses, hyperkalemia (K⁺ >5.5 mEq/L) occurs in 10 to 15% of patients within the first year [1].

Rosuvastatin itself does not directly raise potassium. A 2019 pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) found no disproportionate hyperkalemia signal for rosuvastatin monotherapy [8]. The concern arises indirectly: statins can rarely cause rhabdomyolysis, and muscle breakdown releases intracellular potassium. In a patient already on spironolactone with a baseline K⁺ of 5.0 mEq/L, even a modest CK elevation could push potassium into a dangerous range.

Dr. Matthew Budoff, Professor of Medicine at the Lundquist Institute, has noted: "The combination is safe for the vast majority of patients. The small subset who need vigilance are those with eGFR below 45, concurrent ACE inhibitors or ARBs, or baseline potassium above 5.0."

Severity Rating Across DDI Databases

Major drug interaction databases classify this combination consistently:

The Lexicomp database rates spironolactone plus rosuvastatin as "no significant interaction detected." Micromedex does not list a direct monograph for the pair. The Clinical Pharmacology database flags only the class-level potassium advisory that applies to all mineralocorticoid receptor antagonists combined with any medication in a patient on potassium-sparing therapy [9].

This stands in contrast to genuinely high-risk statin combinations. Simvastatin plus gemfibrozil carries a "contraindicated" rating due to documented 2.8-fold AUC increase and FDA-confirmed rhabdomyolysis cases [10]. The spironolactone-rosuvastatin pair does not approach this threshold.

Monitoring Protocol

For patients taking both spironolactone (any indication) and rosuvastatin, the following monitoring protocol aligns with Endocrine Society and ACC/AHA lipid guidelines:

Baseline (before co-initiation):

• Comprehensive metabolic panel including potassium, creatinine, eGFR
• Fasting lipid panel
• CK level (only if patient reports baseline myalgia)
• Hepatic transaminases (ALT)

Week 1 after co-initiation:

• Repeat potassium. If K⁺ >5.5 mEq/L, reduce spironolactone dose or add dietary potassium restriction before considering statin discontinuation.

Month 3:

• Repeat potassium, creatinine, lipid panel
• Assess for myalgia symptoms

Ongoing (every 6 to 12 months):

• Potassium, renal function, lipid panel
• CK only if symptomatic

Dose Adjustment Guidance

No dose reduction of either drug is required solely because of co-administration. The FDA label for rosuvastatin recommends a maximum of 20 mg daily when combined with "certain OATP1B1 inhibitors" but lists specific agents (lopinavir/ritonavir, atazanavir/ritonavir, simeprevir) [4]. Spironolactone is not among them.

For acne patients on spironolactone 50 to 100 mg daily, standard rosuvastatin dosing (5 to 40 mg) applies without modification. For heart-failure patients on spironolactone 25 to 50 mg daily who initiate rosuvastatin, the ACC/AHA guideline recommendation of moderate-intensity statin therapy (rosuvastatin 5 to 10 mg) is appropriate and carries no incremental interaction risk [11].

One practical consideration: both drugs are best taken in the evening for their respective pharmacodynamic reasons (nocturnal aldosterone surge for spironolactone efficacy, nocturnal hepatic cholesterol synthesis for statin benefit), so single-timepoint dosing is reasonable.

Special Populations Requiring Extra Caution

Chronic kidney disease (eGFR <45 mL/min/1.73m²): Spironolactone hyperkalemia risk doubles. Rosuvastatin 5 mg starting dose is recommended per FDA labeling for severe renal impairment. Monitor potassium weekly for the first month.

Patients on triple RAAS blockade: Adding spironolactone to an ACE inhibitor or ARB already raises hyperkalemia incidence to 5 to 12% [12]. The statin adds negligible potassium risk, but these patients warrant monthly potassium checks regardless.

Elderly women (age >75): Higher rosuvastatin plasma levels occur due to reduced OATP activity with aging. The STOMP trial showed statin-related myalgia occurs in approximately 9.4% of patients on high-intensity therapy [13]. Starting rosuvastatin at 5 mg in elderly women already on spironolactone for acne or hirsutism is prudent.

Patients on potassium supplements or potassium-rich diets: Discontinue supplemental KCl before initiating spironolactone. The 2022 AHA dietary potassium statement recommends caution with high-potassium diets in patients on mineralocorticoid receptor antagonists [14].

What About Other Statins?

If a clinician prefers to avoid even the theoretical OATP concern, pravastatin offers an alternative with no OATP1B1 dependence and minimal CYP metabolism. Pitavastatin is another option with OATP1B1 uptake but no CYP3A4 involvement.

Atorvastatin and simvastatin share CYP3A4 metabolism with spironolactone, creating a more relevant (though still minor) pharmacokinetic overlap. A 2017 population pharmacokinetic study found that spironolactone co-administration increased simvastatin AUC by approximately 15% in heart-failure patients (N=42), though this did not reach statistical significance [15]. Rosuvastatin avoids this pathway entirely.

The 2018 ACC Expert Consensus on non-statin therapies reaffirmed that rosuvastatin and pravastatin carry the lowest drug interaction burden among available statins [11].

Patient Counseling Points

Patients prescribed both medications should receive the following instructions:

Report unexplained muscle pain, weakness, or dark urine immediately. These symptoms warrant urgent CK and potassium measurement. Avoid potassium salt substitutes (such as Morton Lite Salt) while on spironolactone. Grapefruit juice does not affect rosuvastatin but may modestly increase spironolactone exposure through CYP3A4 inhibition. Limit intake to one serving daily.

Do not stop either medication without physician guidance. Abrupt spironolactone discontinuation can cause rebound aldosterone effects with sodium retention and blood pressure spikes. Abrupt statin cessation may increase cardiovascular event risk in high-risk patients, as demonstrated in the PRIMO registry data [16].

Women using spironolactone for acne must maintain reliable contraception due to its anti-androgen effects and Category X pregnancy classification. Rosuvastatin is also contraindicated in pregnancy. Both drugs require discontinuation at least one month before planned conception.

Summary of Evidence

The spironolactone-rosuvastatin combination carries no FDA-labeled contraindication, no documented pharmacokinetic interaction of clinical significance, and a manageable pharmacodynamic potassium consideration that applies to all spironolactone combinations. Standard monitoring protocols suffice. Rosuvastatin's minimal CYP metabolism and spironolactone's weak OATP inhibitory potency at therapeutic concentrations make this one of the lowest-risk statin-MRA pairings available.

Baseline potassium, a 1-week recheck, then quarterly labs represent the minimum monitoring standard for any patient on spironolactone regardless of statin co-therapy.